ArticleBrain and behavior2025
MicroRNA Signatures Predict Brain Amyloidosis and Neurodegeneration in Alzheimer's Disease: Insights from [
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- MicroRNA-223 Enhances Microglia-Dependent Clearance of Amyloid Beta Plaques and Ameliorates Behavioral Deficits in a Mouse Model of Alzheimer's Disease.bioRxiv : the preprint server for biology · 2026Article
- Role and mechanism of LINC00662 via targeting let-7 g-5p in sevoflurane-induced cognitive impairment in rats.BMC anesthesiology · 2026Article
- Comparison of multi-miRNA models from donor-matched plasma and cerebrospinal fluid as candidate biomarkers for Alzheimer's disease prediction.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlzheimer's disease (AD) is a neurodegenerative disease primarily manifesting with cognitive decline. This study aimed to investigate the alterations in microRNAs in patients across AD continuum as potential biomarkers.
methodData were extracted from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, including microRNA levels in the serum and cerebrospinal fluid (CSF) of patients across AD continuum. We analyzed the associations between microRNA levels and previously known AD biomarkers, such as amyloid beta (Aβ) accumulations in the brain and glucose reuptake values using positron emission tomography ([
findingsThe study found a significant positive correlation between CSF levels of miR-210-3p and Aβ accumulations in the brain (B = 4.69). Conversely, miR-223-3p levels were significantly lower in APOE-ε4 carriers. Significant negative correlations were also observed between glucose reuptake and several miRNAs in the AD group. Specifically, plasma levels of let-7g-5p, mir-423-5p, and mir-660-5p were negatively associated with glucose reuptake in the brain.
conclusionElevated levels of miR-210-3p correlate with Aβ accumulation, supporting previous findings of increased levels of certain microRNAs in patients with MCI and AD. Our findings highlight the potential of microRNAs as biomarkers of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.